Beam Therapeutics Inc (BEAM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 4:39 PM ET
Beam Therapeutics Inc (BEAM) Stock Chart
Beam Therapeutics (BEAM) has a latest price of $20.65 on Nov 17, 2026, 46.0% below its 52-week high of $38.26. Its price fell 4.9% over the past 12 months. The month-end price fell 69.3% over the 5 years through Oct 2026, a compound annual decline of 21.0%.
Price Chart
From Feb 2020 to Oct 2026, its highest month-end close was $128.71 in Jun 2021 and its lowest $15.83 in May 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart BEAM with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for BEAM.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 29.0%, and over 6 months it fell 21.6%. The month-end price rose 28.8% over the 3 years through Oct 2026, a compound annual rate of 8.8%.
| Period | Change |
|---|---|
| 1 month | -14.6% |
| 3 months | -29.0% |
| 6 months | -21.6% |
| 12 months | -4.9% |
| 12 months, with dividends | -4.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +28.8% | +8.8% |
| 5 years | -69.3% | -21.0% |
Price by Year
Its best calendar year was 2025, when the price rose 11.8%, and its weakest was 2022, when it fell 50.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $27.23 | -1.8% |
| 2025 | $27.72 | +11.8% |
| 2024 | $24.80 | -8.9% |
| 2023 | $27.22 | -30.4% |
| 2022 | $39.11 | -50.9% |
| 2021 | $79.69 | -2.4% |
Trading Range
The price is 16.9% below its 50-day average of $24.85 and 25.7% below its 200-day average of $27.80.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $20.65 | |
| 52-week high | $38.26 | -46.0% |
| 52-week low | $20.23 | +2.1% |
| 50-day average | $24.85 | -16.9% |
| 200-day average | $27.80 | -25.7% |
Price Risk
Over 3 years, its largest fall from a peak was 67.7%.
| Measure | Value |
|---|---|
| 1-year beta | 2.22 |
| Largest fall, 1 year | -45.5% |
| Largest fall, 3 years | -67.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About BEAM
What is BEAM's 1-year price change?
Beam Therapeutics's price fell 4.9% over the past 12 months. With dividends included, the 12-month total return was -4.9%.
What is BEAM's 5-year price change?
Beam Therapeutics's month-end price fell 69.3% over the 5 years through Oct 2026, a compound annual decline of 21.0%. These figures leave out dividends.
What is BEAM's 52-week high and low?
Beam Therapeutics's 52-week high is $38.26 and its 52-week low is $20.23. Its latest price of $20.65 on Nov 17, 2026 is 46.0% below the high.
What is BEAM's beta?
Beam Therapeutics's 1-year beta against the S&P 500 is 2.22, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 45.5%.
Is the BEAM chart free?
Yes. Advanced Charting for BEAM is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
BEAM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors